Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study
Reich, K., Rich, P., Maari, C., Bissonnette, R., Leonardi, C., Menter, A., Igarashi, A., Klekotka, P., Patel, D., Li, J., Tuttle, J., Morgan‐Cox, M., Edson‐Heredia, E., Friedrich, S., Papp, K.
Published in British journal of dermatology (1951) (01.07.2019)
Published in British journal of dermatology (1951) (01.07.2019)
Get full text
Journal Article
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
Isenberg, D A, Petri, M, Kalunian, K, Tanaka, Y, Urowitz, M B, Hoffman, R W, Morgan-Cox, M, Iikuni, N, Silk, M, Wallace, D J
Published in Annals of the rheumatic diseases (01.02.2016)
Published in Annals of the rheumatic diseases (01.02.2016)
Get full text
Journal Article
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
Merrill, J T, van Vollenhoven, R F, Buyon, J P, Furie, R A, Stohl, W, Morgan-Cox, M, Dickson, C, Anderson, P W, Lee, C, Berclaz, P-Y, Dörner, T
Published in Annals of the rheumatic diseases (01.02.2016)
Published in Annals of the rheumatic diseases (01.02.2016)
Get full text
Journal Article
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials
Isenberg, D., Merrill, J., Hoffman, R., Linnik, M., Morgan-Cox, M., Veenhuizen, M., Iikuni, N., Dickson, C., Silk, M., Wallace, D., Dörner, T.
Published in Annals of the rheumatic diseases (01.06.2015)
Published in Annals of the rheumatic diseases (01.06.2015)
Get full text
Journal Article
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1
Isenberg, D., Merrill, J., Hoffman, R., Linnik, M., Morgan-Cox, M., Veenhuizen, M., Iikuni, N., Dickson, C., Silk, M., Wallace, D., Dörner, T.
Published in Annals of the rheumatic diseases (01.06.2015)
Published in Annals of the rheumatic diseases (01.06.2015)
Get full text
Journal Article
28 Drivers of the sle responder index (sri-5) endpoint in clinical trials of sle
Kalunian, K, Urowitz, M, Isenberg, D, Merrill, J, Petri, M, Furie, R, Morgan-Cox, MA, Taha, R, Silk, M, Linnik, M
Published in Lupus science & medicine (01.03.2017)
Published in Lupus science & medicine (01.03.2017)
Get full text
Journal Article
24 A molecular signature based on ifn gene signature and serology defines two populations of patients with different baseline disease activity
Petri, M, Kalunian, K, Urowitz, M, Furie, R, Morgan-Cox, MA, Silk, M, Dow, E, Higgs, R, Watts, S, Isenberg, D, Linnik, M
Published in Lupus science & medicine (01.03.2017)
Published in Lupus science & medicine (01.03.2017)
Get full text
Journal Article